Abstracts

VIRUS PANEL CLASSIFICATION: A STRATEGY TOWARD DELINEATION OF PLASMA bNAb ACTIVITY

Background: Dissecting broadly neutralizing antibody (bnAb) specificity in polyclonal plasma in HIV-1 infection and post vaccination remains challenging. Delineation methods comparing plasma neutralization patterns against large virus panels with those of epitope-mapped bnAbs are widely used. Common to the current approaches is their inability to resolve the presence of multiple bnAb specificities, or, in rare…

INFERRING IMMUNOGENIC PROPERTIES OF ENV TRIMERS BY REACTIVITY TO bNAb INDUCER PLASMA

Background: Identification of HIV-1 envelope (Env) trimers with the ability to induce broadly neutralizing antibodies (bnAbs) remains critical for HIV-1 vaccine development. Here, we used the XbnAb cohort, comprising bnAb inducers (N&#3f304), and non-neutralizing (nnAb) controls (N&#3f304) identified in the Swiss 4.5k study (Rusert Nat Med 2016), to investigate the reactivity of 29 candidate Env…

SINGLE-CELL QUANTIFICATION OF HIV-1 AND LENTIVIRAL VECTOR IN GENE THERAPY STUDIES

Background: Lentiviral-based vector therapies, which include many CAR-T and gene-modified cell therapies, are at the forefront of HIV-1 cure research. However, sequence homology between these lentiviral vectors and HIV-1 creates challenges with quantifying both cellular HIV burden or lentiviral DNA. As a result, we developed a novel single-cell in droplet (scd)PCR method to co-quantify genomic…

ASSESSING IMMUNOGENICITY BARRIERS OF THE HIV-1 ENVELOPE TRIMER

Background: Understanding the counterbalance of epitope shielding and accessibility on HIV-1 envelope (Env) trimers is essential to guide immunogen selection for broadly neutralizing antibody (bnAb) based vaccines. To investigate the antigenic space of highly stabilized Env trimers, we here created a novel strategy, DARPin Antigenicity Analysis (DANA), based on synthetic, high diversity Designed Ankyrin Repeat…

LONG-TERM LIVER EVENTS IN PATIENTS WITH HCV CHRONIC INFECTION AFTER SVR

Background: Despite achieving sustained viral response (SVR) with direct-acting antivirals (DAA), some individuals with HCV chronic infection remains at risk of developing liver complications. After SVR, there is a temporal pattern of appearance of liver complications depending on the type of event. Thus, ascites and hepatic encephalopathy (HE) usually present earlier after HCV cure. In…